Increasing high-density lipoprotein cholesterol: an update on fenofibrate (Q34491350)

2 August 2017

1 reference

title

Increasing high-density lipoprotein cholesterol: an update on fenofibrate (English)

1 reference

2 August 2017

0 references

1 reference

Després JP

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

American Journal of Cardiology

2 August 2017

published in

1 reference

2 August 2017

volume

88

1 reference

2 August 2017

issue

12A

1 reference

2 August 2017

page(s)

30N-36N

1 reference

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Treatment of obesity: need to focus on high risk abdominally obese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

7 January 2021

Micronised fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Prediction of the therapeutic response to simvastatin by pretreatment lipid concentrations in 2082 subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902150-6

10.1016/S0002-9149(01)02150-6

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference